PRC2 and SWI/SNF Chromatin Remodeling Complexes in Health and Disease von Kadoch, Cigall, Copeland, Robert A, Keilhack, Heike

Volltext

Molecular Pathways: Protein Methyltransferases in Cancer von COPELAND, Robert A

Volltext

Residence Time of Receptor−Ligand Complexes and Its Effect on Biological Function von Tummino, Peter J, Copeland, Robert A

Volltext

The drug–target residence time model: a 10-year retrospective von Copeland, Robert A.

Volltext

Drug Discovery and Chemical Biology of Cancer Epigenetics von Ribich, Scott, Harvey, Darren, Copeland, Robert A.

Volltext

Durable tumor regression in genetically altered malignant rhabdoid tumors by inhibition of methyltransferase EZH2 von Knutson, Sarah K., Warholic, Natalie M., Wigle, Tim J., Klaus, Christine R., Allain, Christina J., Raimondi, Alejandra, Scott, Margaret Porter, Chesworth, Richard, Moyer, Mikel P., Copeland, Robert A., Richon, Victoria M., Pollock, Roy M., Kuntz, Kevin W., Keilhack, Heike

Volltext

Coordinated activities of wild-type plus mutant EZH2 drive tumor-associated hypertrimethylation of lysine 27 on histone H3 (H3K27) in human B-cell lymphomas von Sneeringer, Christopher J., Scott, Margaret Porter, Kuntz, Kevin W., Knutson, Sarah K., Pollock, Roy M., Richon, Victoria M., Copeland, Robert A., Wells, James A.

Volltext

Potent inhibition of DOT1L as treatment of MLL-fusion leukemia von Daigle, Scott R., Olhava, Edward J., Therkelsen, Carly A., Basavapathruni, Aravind, Jin, Lei, Boriack-Sjodin, P. Ann, Allain, Christina J., Klaus, Christine R., Raimondi, Alejandra, Scott, Margaret Porter, Waters, Nigel J., Chesworth, Richard, Moyer, Mikel P., Copeland, Robert A., Richon, Victoria M., Pollock, Roy M.

Volltext

Selective inhibition of EZH2 by EPZ-6438 leads to potent antitumor activity in EZH2-mutant non-Hodgkin lymphoma von Knutson, Sarah K, Kawano, Satoshi, Minoshima, Yukinori, Warholic, Natalie M, Huang, Kuan-Chun, Xiao, Yonghong, Kadowaki, Tadashi, Uesugi, Mai, Kuznetsov, Galina, Kumar, Namita, Wigle, Tim J, Klaus, Christine R, Allain, Christina J, Raimondi, Alejandra, Waters, Nigel J, Smith, Jesse J, Porter-Scott, Margaret, Chesworth, Richard, Moyer, Mikel P, Copeland, Robert A, Richon, Victoria M, Uenaka, Toshimitsu, Pollock, Roy M, Kuntz, Kevin W, Yokoi, Akira, Keilhack, Heike

Volltext

A selective inhibitor of EZH2 blocks H3K27 methylation and kills mutant lymphoma cells von Knutson, Sarah K, Wigle, Tim J, Warholic, Natalie M, Sneeringer, Christopher J, Allain, Christina J, Klaus, Christine R, Sacks, Joelle D, Raimondi, Alejandra, Majer, Christina R, Song, Jeffrey, Scott, Margaret Porter, Jin, Lei, Smith, Jesse J, Olhava, Edward J, Chesworth, Richard, Moyer, Mikel P, Richon, Victoria M, Copeland, Robert A, Keilhack, Heike, Pollock, Roy M, Kuntz, Kevin W

Volltext

Selective Killing of SMARCA2- and SMARCA4-deficient Small Cell Carcinoma of the Ovary, Hypercalcemic Type Cells by Inhibition of EZH2: In Vitro and In Vivo Preclinical Models von Chan-Penebre, Elayne, Armstrong, Kelli, Drew, Allison, Grassian, Alexandra R, Feldman, Igor, Knutson, Sarah K, Kuplast-Barr, Kristy, Roche, Maria, Campbell, John, Ho, Peter, Copeland, Robert A, Chesworth, Richard, Smith, Jesse J, Keilhack, Heike, Ribich, Scott A

Volltext

The Importance of Being Me: Magic Methyls, Methyltransferase Inhibitors, and the Discovery of Tazemetostat von Kuntz, Kevin W, Campbell, John E, Keilhack, Heike, Pollock, Roy M, Knutson, Sarah K, Porter-Scott, Margaret, Richon, Victoria M, Sneeringer, Chris J, Wigle, Tim J, Allain, Christina J, Majer, Christina R, Moyer, Mikel P, Copeland, Robert A, Chesworth, Richard

Volltext

Preclinical Evidence of Anti-Tumor Activity Induced by EZH2 Inhibition in Human Models of Synovial Sarcoma von Kawano, Satoshi, Grassian, Alexandra R, Tsuda, Masumi, Knutson, Sarah K, Warholic, Natalie M, Kuznetsov, Galina, Xu, Shanqin, Xiao, Yonghong, Pollock, Roy M, Smith, Jesse S, Kuntz, Kevin K, Ribich, Scott, Minoshima, Yukinori, Matsui, Junji, Copeland, Robert A, Tanaka, Shinya, Keilhack, Heike

Volltext

Impact of enzyme concentration and residence time on apparent activity recovery in jump dilution analysis von Copeland, Robert A., Basavapathruni, Aravind, Moyer, Mikel, Scott, Margaret Porter

Volltext

EZH2 Inhibition by Tazemetostat Results in Altered Dependency on B-cell Activation Signaling in DLBCL von Brach, Dorothy, Johnston-Blackwell, Danielle, Drew, Allison, Lingaraj, Trupti, Motwani, Vinny, Warholic, Natalie M, Feldman, Igor, Plescia, Christopher, Smith, Jesse J, Copeland, Robert A, Keilhack, Heike, Chan-Penebre, Elayne, Knutson, Sarah K, Ribich, Scott A, Raimondi, Alejandra, Thomenius, Michael J

Volltext

Synergistic Anti-Tumor Activity of EZH2 Inhibitors and Glucocorticoid Receptor Agonists in Models of Germinal Center Non-Hodgkin Lymphomas von Knutson, Sarah K, Warholic, Natalie M, Johnston, L Danielle, Klaus, Christine R, Wigle, Tim J, Iwanowicz, Dorothy, Littlefield, Bruce A, Porter-Scott, Margaret, Smith, Jesse J, Moyer, Mikel P, Copeland, Robert A, Pollock, Roy M, Kuntz, Kevin W, Raimondi, Alejandra, Keilhack, Heike

Volltext

Epigallocatechin gallate (EGCG), a major component of green tea, is a dual phosphoinositide-3-kinase/mTOR inhibitor von Van Aller, Glenn S., Carson, Jeff D., Tang, Wei, Peng, Hao, Zhao, Lin, Copeland, Robert A., Tummino, Peter J., Luo, Lusong

Volltext

Targeting epigenetic regulators for cancer therapy von Wee, Susan, Dhanak, Dash, Li, Haitao, Armstrong, Scott A., Copeland, Robert A., Sims, Robert, Baylin, Stephen B., Liu, Xiaole Shirley, Schweizer, Liang

Volltext

A687V EZH2 is a gain-of-function mutation found in lymphoma patients von Majer, Christina R., Jin, Lei, Scott, Margaret Porter, Knutson, Sarah K., Kuntz, Kevin W., Keilhack, Heike, Smith, Jesse J., Moyer, Mikel P., Richon, Victoria M., Copeland, Robert A., Wigle, Tim J.

Volltext

Protein methyltransferase inhibitors as precision cancer therapeutics: a decade of discovery von Copeland, Robert A.

Volltext